






AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of ~~treating~~ providing a medical therapeutic treatment of Alzheimer's disease ~~or a dementia of vascular origin~~ comprising administering to a ~~mammal in need thereof~~ human suffering from Alzheimer's disease a therapeutically effective amount of an endothelin antagonist selected from the group consisting of













R=CH₂CO₂H or CH₂CH₂OH,









X=H₂ and Y=CH₂, or

X=O and Y=O,










, and



2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. The method of claim 1 wherein the endothelin antagonist is ~~selected from the group consisting of atrasentan, tezosentan, comprises~~ bosentan, sitaxsentan, enrasentan, BMS-207940, BMS-193884, BMS-182874, J-104132, VML-588/Ro-61-1790, T-0115, TAK-044, BQ-788, BQ123, YM-598, LU-135252, PD-145065, A-127722, ABT-627, A-192621, A-182086, TBC3711, BSF208075, S-0139, TBC2576, TBC3214, PD156707, PD180988, ABT-546, ABT-627, Z1611, RPR118031A, SB247083, SB217242, S-Lu302872, TPC10950, SB209670, and mixtures thereof.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Currently amended) The method of claim 1 further comprising administering a therapeutically effective amount of a ~~second therapeutic agent~~ cholinesterase inhibitor useful in the medical therapeutic treatment of Alzheimer's disease ~~or a dementia of vascular origin~~.

14. (Cancelled)

15. (Currently amended) The method of claim ~~14~~ 13 wherein the cholinesterase inhibitor is selected from the group consisting of tacrine, metrifonate, bethanacol, physostigmine, donepezil, rivastigmine, galantamine, and mixtures thereof.

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Currently amended) The method of claim 13 wherein the endothelin antagonist and ~~second therapeutic agent~~ the cholinesterase inhibitor are administered simultaneously.

20. (Currently amended) The method of claim 13 wherein the endothelin antagonist and ~~second therapeutic agent~~ the cholinesterase inhibitor are administered from a single composition.

21. (Currently amended) The method of claim 13 wherein the endothelin antagonist and ~~second therapeutic agent~~ the cholinesterase inhibitor are administered from separate compositions.

22. (Currently amended) The method of claim 13 wherein the endothelin antagonist and ~~second therapeutic agent~~ the cholinesterase inhibitor are administered separately.

23. (Currently amended) The method of claim 22 wherein the endothelin antagonist is administered prior to the ~~second therapeutic agent~~ cholinesterase inhibitor.

24. (Currently amended) The method of claim 22 wherein the endothelin antagonist is administered after the ~~second therapeutic agent~~ cholinesterase inhibitor.

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)